191 related articles for article (PubMed ID: 36580664)
21. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions.
Golder M; Pruss CM; Hegadorn C; Mewburn J; Laverty K; Sponagle K; Lillicrap D
Blood; 2010 Jun; 115(23):4862-9. PubMed ID: 20371742
[TBL] [Abstract][Full Text] [Related]
22. Enhanced Local Disorder in a Clinically Elusive von Willebrand Factor Provokes High-Affinity Platelet Clumping.
Tischer A; Machha VR; Frontroth JP; Brehm MA; Obser T; Schneppenheim R; Mayne L; Walter Englander S; Auton M
J Mol Biol; 2017 Jul; 429(14):2161-2177. PubMed ID: 28533135
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
[TBL] [Abstract][Full Text] [Related]
24. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha.
Martin C; Morales LD; Cruz MA
J Thromb Haemost; 2007 Jul; 5(7):1363-70. PubMed ID: 17389010
[TBL] [Abstract][Full Text] [Related]
25. Alterations in the intrinsic properties of the GPIbalpha-VWF tether bond define the kinetics of the platelet-type von Willebrand disease mutation, Gly233Val.
Doggett TA; Girdhar G; Lawshe A; Miller JL; Laurenzi IJ; Diamond SL; Diacovo TG
Blood; 2003 Jul; 102(1):152-60. PubMed ID: 12637314
[TBL] [Abstract][Full Text] [Related]
26. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
[TBL] [Abstract][Full Text] [Related]
27. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
[TBL] [Abstract][Full Text] [Related]
28. How I treat type 2B von Willebrand disease.
Kruse-Jarres R; Johnsen JM
Blood; 2018 Mar; 131(12):1292-1300. PubMed ID: 29378695
[TBL] [Abstract][Full Text] [Related]
29. Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality.
Castaman G; Federici AB
Semin Thromb Hemost; 2016 Jul; 42(5):478-82. PubMed ID: 27148840
[TBL] [Abstract][Full Text] [Related]
30. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease.
Baronciani L; Federici AB; Cozzi G; Canciani MT; Mannucci PM
J Thromb Haemost; 2007 Feb; 5(2):282-8. PubMed ID: 17155947
[TBL] [Abstract][Full Text] [Related]
31. Desialylation of O-glycans activates von Willebrand factor by destabilizing its autoinhibitory module.
Voos KM; Cao W; Arce NA; Legan ER; Wang Y; Shajahan A; Azadi P; Lollar P; Zhang XF; Li R
J Thromb Haemost; 2022 Jan; 20(1):196-207. PubMed ID: 34529349
[TBL] [Abstract][Full Text] [Related]
32. Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance.
Wohner N; Legendre P; Casari C; Christophe OD; Lenting PJ; Denis CV
J Thromb Haemost; 2015 May; 13(5):815-20. PubMed ID: 25728415
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets.
Cooney KA; Ginsburg D
Blood; 1996 Mar; 87(6):2322-8. PubMed ID: 8630394
[TBL] [Abstract][Full Text] [Related]
34. Thermodynamic stabilization of von Willebrand factor A1 domain induces protein loss of function.
Sandoval-Pérez A; Mejía-Restrepo V; Aponte-Santamaría C
Proteins; 2022 Dec; 90(12):2058-2066. PubMed ID: 35833249
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics of von Willebrand disease.
Mazurier C; Ribba AS; Gaucher C; Meyer D
Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
[TBL] [Abstract][Full Text] [Related]
36. A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.
Adam F; Casari C; Prévost N; Kauskot A; Loubière C; Legendre P; Repérant C; Baruch D; Rosa JP; Bryckaert M; de Groot PG; Christophe OD; Lenting PJ; Denis CV
Sci Rep; 2016 May; 6():26306. PubMed ID: 27212476
[TBL] [Abstract][Full Text] [Related]
37. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion.
Miura S; Li CQ; Cao Z; Wang H; Wardell MR; Sadler JE
J Biol Chem; 2000 Mar; 275(11):7539-46. PubMed ID: 10713059
[TBL] [Abstract][Full Text] [Related]
38. The Von Willebrand Factor A1-Collagen III Interaction Is Independent of Conformation and Type 2 Von Willebrand Disease Phenotype.
Machha VR; Tischer A; Moon-Tasson L; Auton M
J Mol Biol; 2017 Jan; 429(1):32-47. PubMed ID: 27889474
[TBL] [Abstract][Full Text] [Related]
39. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.
Jenkins PV; Pasi KJ; Perkins SJ
Blood; 1998 Mar; 91(6):2032-44. PubMed ID: 9490688
[TBL] [Abstract][Full Text] [Related]
40. Functional studies on platelet adhesion with recombinant von Willebrand factor type 2B mutants R543Q and R543W under conditions of flow.
Lankhof H; Damas C; Schiphorst ME; IJsseldijk MJ; Bracke M; Sixma JJ; Vink T; de Groot PG
Blood; 1997 Apr; 89(8):2766-72. PubMed ID: 9108394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
